Halozyme Therapeutics, Inc. (BIT:1HALO)
Italy · Delayed Price · Currency is EUR | Market Cap | 12.29B +82.8% |
| Revenue (ttm) | 1.46B +41.2% |
| Net Income | 362.02M -25.8% |
| EPS | 2.96 -22.5% |
| Shares Out | n/a |
| PE Ratio | 33.95 |
| Forward PE | 11.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 265 |
| Open | 93.26 |
| Previous Close | 96.66 |
| Day's Range | 88.72 - 93.50 |
| 52-Week Range | 51.28 - 103.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 3, 2026 |
About Halozyme Therapeutics
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini... [Read more]
Financial Performance
In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.
Financial numbers in USD Financial StatementsNews
Halozyme price target raised to $130 from $105 at TD Cowen
TD Cowen raised the firm’s price target on Halozyme (HALO) to $130 from $105 and keeps a Buy rating on the shares. The firm adjusted targets in the life science…
Halozyme price target raised to $130 from $115 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme (HALO) to $130 from $115 and keeps a Buy rating on the shares. The firm says second European…
Halozyme price target raised to $78 from $70 at JPMorgan
JPMorgan raised the firm’s price target on Halozyme (HALO) to $78 from $70 and keeps a Neutral rating on the shares. The firm updated the company’s model ahead of the…
Halozyme wins court order to block Merck's injected Keytruda in select European markets
Biopharma company Halozyme said on Wednesday that a Dutch patent court ruled in its favor against Merck , ordering the drugmaker to halt the manufacture and sale of injectable Keytruda in eight Euro...
Halozyme announces Dutch court of the Hague found Merck infringed patents
Halozyme Therapeutics (HALO) announced that the specialized Dutch patent court of the Hague has found Merck (MRK) to be infringing one of its MDASE patents, EP 2,797,622 and ordered Merck’s…
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to...
Halozyme expands global collaboration and license agreement with Argenx
Halozyme Therapeutics (HALO) announced that it has expanded its global collaboration and license agreement with Argenx (ARGX) to develop and commercialize ENHANZE with two additional exclusive targets...
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targets SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Comp...
Halozyme Announces Appointment of Jim Daly to its Board of Directors
SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors.
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% conv...
Halozyme announces proposed offering of $1.05B of 2033 convertible senior notes
Halozyme (HALO) Therapeutics “announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033. The Com...
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other fac...
Halozyme Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The conference highlighted strong revenue growth driven by diversified royalty streams from subcutaneous delivery technologies, with ENHANZE and Hypercon platforms expanding rapidly. Guidance was raised on robust product launches and a deep pipeline, while patent strategy and minimal IRA impact support long-term outlook.
Halozyme Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Expansion into China and AI-driven efficiencies are fueling growth, with record Q2 revenue and a diversified royalty base. Multiple new deals and product launches are expected, while Hypercon and Surf Bio platforms aim to sustain long-term royalty growth.
Record Revenue Growth Boosts Halozyme Shares
Institutions have pushed Halozyme Therapeutics, Inc. (HALO) shares up 769% since March 2014.
Halozyme Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Record revenue growth driven by ENHANZE and new subcutaneous launches, with expanding pipeline and five new deals supporting future royalties. SubQ delivery is now a commercial mandate, and HyperCon technology is advancing with robust partner interest. Capital allocation remains disciplined, balancing platform investment, buybacks, and selective M&A.
Halozyme to Participate at Upcoming Investor Conferences
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Ch...
Halozyme Appoints Dannielle Appelhans to its Board of Directors
SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings mor...
Halozyme price target raised to $95 from $75 at Wells Fargo
Wells Fargo raised the firm’s price target on Halozyme (HALO) to $95 from $75 and keeps an Equal Weight rating on the shares. The firm cites a Q2 beat/raise driven…
Halozyme price target raised to $105 from $93 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Halozyme (HALO) to $105 from $93 and keeps an Overweight rating on the shares.
Halozyme price target raised to $105 from $96 at TD Cowen
TD Cowen raised the firm’s price target on Halozyme (HALO) to $105 from $96 and keeps a Buy rating on the shares. The firm updated its model following strong Q2…
Halozyme price target raised to $95 from $75 at Wells Fargo
Wells Fargo raised the firm’s price target on Halozyme (HALO) to $95 from $75 and keeps an Equal Weight rating on the shares. The firm notes Q2 beat/raise was driven…
Leerink upgraded Halozyme to Outperform on growth, market leadership
As previously reported, Leerink upgraded Halozyme (HALO) to Outperform from Market Perform with a price target of $110, up from $83. The firm expects additional upside to consensus revenue and…
Halozyme upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Halozyme (HALO) to Outperform from Market Perform with a price target of $110, up from $83.